Boc-D-精氨酸 | 200122-49-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: Boc-D-精氨酸
• 中文别名: N^A-BOC-N^W-(4-甲氧基-2,3,6-三甲基苯基磺酰基)-D-精氨酸；N2-[叔丁氧羰基]-N5-[亚氨基[[(4-甲氧基-2,3,6-三甲基苯基)磺酰基]氨基]甲基]-D-鸟氨酸
• 英文名称: (R)-5-({Amino-[(E)-4-methoxy-2,3,6-trimethyl-benzenesulfonylimino]-methyl}-amino)-2-tert-butoxycarbonylamino-pentanoic acid
• 英文别名: Boc-D-Arg(Mtr)-OH；(2R)-5-[[amino-[(4-methoxy-2,3,6-trimethylphenyl)sulfonylamino]methylidene]amino]-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid
• CAS: 200122-49-2
• 化学式: C₂₁H₃₄N₄O₇S
• 分子量: 486.59
• InChiKey: CXZHJRGYWGPJSD-OAHLLOKOSA-N

物化性质

• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  182
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Boc-D-精氨酸 在 N-甲基吗啉 、 盐酸 、 氯甲酸异丙酯 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 乙酸乙酯 、 甲苯 为溶剂， 反应 11.67h， 生成 (S)-2-Amino-N-{(S)-1-[(R)-4-({amino-[(E)-4-methoxy-2,3,6-trimethyl-benzenesulfonylimino]-methyl}-amino)-1-(2-chloro-acetyl)-butylcarbamoyl]-2-phenyl-ethyl}-3-phenyl-propionamide
  参考文献：
  名称：

  Synthesis of EF24−Tripeptide Chloromethyl Ketone:  A Novel Curcumin-Related Anticancer Drug Delivery System

  摘要：

  The blood coagulation cascade includes a step in which the soluble protein, factor VIIa (fVIIa), complexes with its transmembrane receptor, tissue factor (TF). The fVIIa/TF protein-protein complex is subsequently drawn into the cell by endocytosis. The observation that TF is aberrantly and abundantly expressed on many cancer cells offers an opportunity to specifically target those cells with an effective anticancer drug. Thus, we propose a new drug delivery system, drug-linker-Phe-Phe-Arg-mk-fVIIa, which can associate with TF on the surface of cancer cells, but release the cytotoxic agent in the cytoplasm. Synthetic procedures have been developed for the preparation of phenylalanine-phenylalanine-arginine chloromethyl ketone, (FFRck) followed by coupling with the cytotoxin EF24 and subsequently fVIIa to give EF-24-FFRmk-fVIIa. When breast cancer cells (MDA-MB-231) and human melanoma cells (RPMI-7951) are treated with the complex, the cells are arrested to a greater extent than EF24 alone by comparison with controls.

  DOI：

  10.1021/jm051141k

文献信息

• Inhibitors of growth factor activation enzymes
  申请人：Janetka James W.

  公开号：US11130780B2

  公开（公告）日：2021-09-28

  The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.

  本发明一般涉及可用于抑制一种或多种肝细胞生长因子激活剂、淀粉酶、肝素、Xa因子或凝血酶的化合物。 本发明还涉及使用抑制剂化合物的各种方法，包括通过向有需要的受试者施用有效量的抑制剂来治疗恶性肿瘤、恶性肿瘤前期病症或癌症。
• INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES
  申请人：Janetka James W.

  公开号：US20180066015A1

  公开（公告）日：2018-03-08

  The present invention generally relates to compounds that are useful for inhibiting one or more of hepatocyte growth factor activator, matriptase, hepsin, Factor Xa, or thrombin. The present invention also relates to various methods of using the inhibitor compounds including treating a malignancy, a pre-malignant condition, or cancer by administering an effective amount of the inhibitor to a subject in need thereof.